四逆散改善Mdr2-/-小鼠胆汁淤积性肝纤维化作用

被引:5
作者
范桂芳
蔡雅洁
李方红
李宇飞
刘闰平
机构
[1] 北京中医药大学中药学院
关键词
四逆散; 胆汁淤积性肝纤维化; 转录组学; 炎症; 细胞焦亡; 胆汁酸代谢;
D O I
暂无
中图分类号
R285.5 [中药实验药理];
学科分类号
100806 [中药药理学];
摘要
目的 研究四逆散对Mdr2(Abcb4)基因缺陷(Mdr2-/-)小鼠胆汁淤积性肝纤维化的缓解作用,并探究其作用机制。方法 C57BL/6J小鼠作为对照组;C57BL/6J背景的Mdr2-/-小鼠作为模型小鼠,设模型组和四逆散低、高剂量(按生药量计为3.12、6.24 g·kg-1)组。四逆散组连续3周ig给予四逆散水提物,每天1次,对照组给予纯水。试剂盒法检测血清丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、总胆汁酸水平;取肝脏、脾脏称质量,计算肝脏、脾脏系数;结合小鼠肝组织HE染色,Masson染色,纤连蛋白(Fibronectin)、细胞角蛋白19(CK19)的免疫组化染色,明确四逆散对Mdr2-/-小鼠肝纤维化及胆汁淤积的影响。基于小鼠肝脏转录组学测序技术,挖掘四逆散改善Mdr2-/-小鼠肝损伤的作用靶点,并通过实时荧光定量PCR(qRT-PCR)法检测肝纤维化[fibronectin(Fn1)、胶原蛋白1(Col1a1)、角蛋白19(krt19)]、炎症[白细胞介素-1β(Il1β)、Il6、肿瘤坏死因子-α(Tnfα)、一氧化氮合成酶(Inos)]、细胞焦亡[凋亡相关斑点样蛋白(Pycard)、Il18]、胆汁酸合成[细胞色素P450家族成员7A1(Cyp7a1)]及转运[胆盐输出泵(Abcb11)、ATP结合盒转运蛋白(Abcc3)、钠离子-牛磺胆酸共转运蛋白(Slc10a1)]相关基因的转录水平。结果 与模型组比较,四逆散高剂量显著降低血清总胆汁酸的水平(P<0.05);明显缓解了Mdr2-/-小鼠肝脏中央静脉及胆管周围炎性细胞的浸润和胶原纤维的沉积,并显著抑制胆管反应的发生。转录组学及qRT-PCR结果共同表明,四逆散下调Mdr2-/-小鼠肝脏纤维化、炎症、细胞焦亡相关基因的转录(P<0.05);同时,四逆散下调胆汁酸合成关键限速酶调控基因Cyp7a1和调控胆汁酸向肝内转运的基因Slc10a1的转录,并上调调控胆汁酸外排的基因Abcb11、Abcc3的转录。结论 四逆散能缓解Mdr2-/-小鼠胆汁淤积性肝纤维化,机制可能与其调控炎症反应、细胞焦亡以及胆汁酸的合成和转运有关。
引用
收藏
页码:291 / 301
页数:11
相关论文
共 20 条
[1]
APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis [J].
You, Hong ;
Ma, Xiong ;
Efe, Cumali ;
Wang, Guiqiang ;
Jeong, Sook-Hyang ;
Abe, Kazumichi ;
Duan, Weijia ;
Chen, Sha ;
Kong, Yuanyuan ;
Zhang, Dong ;
Wei, Lai ;
Wang, Fu-Sheng ;
Lin, Han-Chieh ;
Yang, Jin Mo ;
Tanwandee, Tawesak ;
Gani, Rino A. ;
Payawal, Diana A. ;
Sharma, Barjesh C. ;
Hou, Jinlin ;
Yokosuka, Osamu ;
Dokmeci, A. Kadir ;
Crawford, Darrell ;
Kao, Jia-Horng ;
Piratvisuth, Teerha ;
Suh, Dong Jin ;
Lesmana, Laurentius A. ;
Sollano, Jose ;
Lau, George ;
Sarin, Shiv K. ;
Omata, Masao ;
Tanaka, Atsushi ;
Jia, Jidong .
HEPATOLOGY INTERNATIONAL, 2022, 16 (01) :1-23
[2]
Dolomiaea souliei ethyl acetate extract protected against α-naphthylisothiocyanate-induced acute intrahepatic cholestasis through regulation of farnesoid x receptor-mediated bile acid metabolism [J].
Meng, FanCheng ;
Zong, Wei ;
Wei, XiaoDong ;
Tao, YunYi ;
Wang, GuoWei ;
Liao, ZhiHua ;
Chen, Min .
PHYTOMEDICINE, 2021, 87
[3]
Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents [J].
Hasegawa, Sho ;
Yoneda, Masato ;
Kurita, Yusuke ;
Nogami, Asako ;
Honda, Yasushi ;
Hosono, Kunihiro ;
Nakajima, Atsushi .
DRUGS, 2021, 81 (10) :1181-1192
[4]
Si-Ni-San ameliorates chronic colitis by modulating type I interferons-mediated inflammation [J].
Cai, Yajie ;
Xu, Bing ;
Zhou, Fei ;
Wu, Jianzhi ;
Li, Shuo ;
Zheng, Qi ;
Li, Yajing ;
Li, Xiaojiaoyang ;
Gao, Feng ;
Dong, Shifen ;
Liu, Runping .
PHYTOMEDICINE, 2021, 84
[5]
Primary biliary cholangitis: pathogenesis and therapeutic opportunities [J].
Gulamhusein, Aliya F. ;
Hirschfield, Gideon M. .
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2020, 17 (02) :93-110
[6]
Drug Therapies for Chronic Cholestatic Liver Diseases.[J].Martin Wagner;Peter Fickert.Annual Review of Pharmacology and Toxicology.2020, 1
[7]
Cholangiocyte pathobiology [J].
Banales, Jesus M. ;
Huebert, Robert C. ;
Karlsen, Tom ;
Strazzabosco, Mario ;
LaRusso, Nicholas F. ;
Gores, Gregory J. .
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2019, 16 (05) :269-281
[8]
Primary biliary cholangitis: A tale of epigenetically-induced secretory failure? [J].
Rodrigues, Pedro M. ;
Perugorria, Maria J. ;
Santos-Laso, Alvaro ;
Bujanda, Luis ;
Beuers, Ulrich ;
Banales, Jesus M. .
JOURNAL OF HEPATOLOGY, 2018, 69 (06) :1371-1383
[9]
An FXR Agonist Reduces Bile Acid Synthesis Independently of Increases in FGF19 in Healthy Volunteers [J].
Al-Khaifi, Amani ;
Rudling, Mats ;
Angelin, Bo .
GASTROENTEROLOGY, 2018, 155 (04) :1012-1016
[10]
Role of inflammation and proinflammatory cytokines in cholangiocyte pathophysiology [J].
Pinto, Claudio ;
Giordano, Debora Maria ;
Maroni, Luca ;
Marzioni, Marco .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2018, 1864 (04) :1270-1278